journal article·2024-09-01Open access

From formulation to structure: 3D electron diffraction for the structure solution of a new indomethacin polymorph from an amorphous solid dispersion

Helen W. Leung, Royston C. B. Copley, Giulio I. Lampronti, Sarah J. Day, Lucy K. Saunders, Duncan N. Johnstone, Paul A. Midgley

IUCrJ· Volume 11· Issue 5

Abstract

3D electron diffraction (3DED) is increasingly employed to determine molecular and crystal structures from micro-crystals. Indomethacin is a well known, marketed, small-molecule non-steroidal anti-inflammatory drug with eight known polymorphic forms, of which four structures have been elucidated to date. Using 3DED, we determined the structure of a new ninth polymorph, σ, found within an amorphous solid dispersion, a product formulation sometimes used for active pharmaceutical ingredients with poor aqueous solubility. Subsequently, we found that σ indomethacin can be produced from direct solvent evaporation using dichloromethane. These results demonstrate the relevance of 3DED within drug development to directly probe product formulations.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Crystallization and Solubility Studies · Drug Solubulity and Delivery Systems · Crystallography and molecular interactions

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (35)

Show source-provided references
1. Andrusenko · Int. J. Pharm. · 2021 · 608 · 12106710.1016/j.ijpharm.2021.121067 ↗
2. Barbas · Cryst. Growth Des. · 2018 · 18 · 374010.1021/acs.cgd.8b00683 ↗
3. Butler · J. Pharm. Sci. · 2010 · 99 · 494010.1002/jps.22217 ↗
4. Chen · J. Am. Chem. Soc. · 2002 · 124 · 1501210.1021/ja017662o ↗
5. Coelho · J. Appl. Cryst. · 2018 · 51 · 21010.1107/S1600576718000183 ↗
6. Donnay · Am. Mineral. · 1937 · 22 · 446
7. Gemmi · ACS Cent. Sci. · 2019 · 5 · 131510.1021/acscentsci.9b00394 ↗
8. Gnutzmann · Cryst. Growth Des. · 2014 · 14 · 644510.1021/cg501287v ↗
9. Gruene · Angew. Chem. Int. Ed. · 2018 · 57 · 1631310.1002/anie.201811318 ↗
10. Guzmán · J. Pharm. Sci. · 2007 · 96 · 268610.1002/jps.20906 ↗
11. He · J. Pharm. Sci. · 2015 · 104 · 323710.1002/jps.24541 ↗
12. Hu · Mol. Pharm. · 2019 · 16 · 497810.1021/acs.molpharmaceut.9b00851 ↗
13. Jones · ACS Cent. Sci. · 2018 · 4 · 158710.1021/acscentsci.8b00760 ↗
14. Karothu · Angew. Chem. Int. Ed. · 2023 · 62 · e20230376110.1002/anie.202303761 ↗
15. Kistenmacher · J. Am. Chem. Soc. · 1972 · 94 · 134010.1021/ja00759a047 ↗
16. Kitaigorodskii · Acta Cryst. · 1965 · 18 · 58510.1107/S0365110X65001391 ↗
17. Klar · Nat. Chem. · 2023 · 15 · 84810.1038/s41557-023-01186-1 ↗
18. Klimakow · Langmuir · 2010 · 26 · 1123310.1021/la100540q ↗
19. Lightowler · Angew. Chem. Int. Ed. · 2024 · 63 · e20231769510.1002/anie.202317695 ↗
20. Lightowler · Angew. Chem. Int. Ed. · 2022 · 61 · e20211498510.1002/anie.202114985 ↗
21. Macrae · J. Appl. Cryst. · 2020 · 53 · 22610.1107/S1600576719014092 ↗
22. Newman, A. & Wenslow, R. (2016). AAPS Open 2:2.10.1186/s41120-016-0003-4 ↗
23. Palatinus · Acta Cryst. B · 2015 · 71 · 74010.1107/S2052520615017023 ↗
24. Peet · Ultramicroscopy · 2019 · 203 · 12510.1016/j.ultramic.2019.02.007 ↗
25. Pham · Mol. Pharm. · 2010 · 7 · 166710.1021/mp100205g ↗
26. Ricarte · Mol. Pharm. · 2019 · 16 · 408910.1021/acs.molpharmaceut.9b00601 ↗
27. Rigaku Oxford Diffraction (2020). CrysAlisPro. Rigaku Oxford Diffraction, Yarnton, UK.
28. S'ari · Mol. Pharm. · 2021 · 18 · 190510.1021/acs.molpharmaceut.0c00918 ↗
29. Schneider · Acta Cryst. D · 2002 · 58 · 177210.1107/S0907444902011678 ↗
30. Sundareswaran · Cryst. Res. Technol. · 2020 · 55 · 200008310.1002/crat.202000083 ↗
31. Surwase · Mol. Pharm. · 2013 · 10 · 447210.1021/mp400299a ↗
32. Van Duong · Mol. Pharm. · 2018 · 15 · 103710.1021/acs.molpharmaceut.7b00930 ↗
33. Vasconcelos · Drug Discovery Today · 2007 · 12 · 106810.1016/j.drudis.2007.09.005 ↗
34. Woollam · CrystEngComm · 2020 · 22 · 749010.1039/D0CE01216E ↗
35. Xie · J. Pharm. Sci. · 2017 · 106 · 10010.1016/j.xphs.2016.06.017 ↗